Vyant Bio (VYNT) 10-Q 15 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 08, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	CANCER GENETICS, INC
Trading Symbol	CGIX
Entity Central Index Key	1,349,929
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding (in shares)		27,746,497

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 4,022	$ 9,541
Accounts receivable, net of allowance for doubtful accounts of 2018 $7,003; 2017 $6,539	10,335	10,958
Assets held for sale	2,058	0
Other current assets	2,622	2,707
Total current assets	19,037	23,206
FIXED ASSETS, net of accumulated depreciation	4,876	5,550
OTHER ASSETS
Restricted cash	350	350
Patents and other intangible assets, net of accumulated amortization	4,375	4,478
Investment in joint venture	244	246
Goodwill	17,257	17,992
Other	305	399
Total other assets	22,531	23,465
Total Assets	46,444	52,221
CURRENT LIABILITIES
Accounts payable and accrued expenses	8,921	8,715
Obligations under capital leases, current portion	319	272
Liabilities held for sale	221	0
Deferred revenue	1,751	516
Line of credit	3,510	4,137
Term note, current portion	6,000	6,000
Total current liabilities	20,722	19,640
Obligations under capital leases	641	624
Deferred rent payable and other	324	360
Warrant liability	3,711	4,403
Deferred revenue, long-term	992	429
Total Liabilities	26,390	25,456
STOCKHOLDERS’ EQUITY
Preferred stock, authorized 9,764 shares, $0.0001 par value, none issued	0	0
Common stock, authorized 100,000 shares, $0.0001 par value, 27,730 and 27,754 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	3	3
Additional paid-in capital	161,801	161,527
Accumulated other comprehensive income	49	69
Accumulated (deficit)	(141,799)	(134,834)
Total Stockholders’ Equity	20,054	26,765
Total Liabilities and Stockholders’ Equity	$ 46,444	$ 52,221

Consolidated Balance Sheets (U3

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, shares authorized (in shares)	9,764,000	9,764,000
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares issued (in shares)	0	0
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock, shares issued (in shares)	27,730,000	27,754,000
Common stock, shares outstanding (in shares)	27,730,000	27,754,000
Allowance for doubtful accounts	$ 7,003	$ 6,539

Consolidated Statements of Oper

Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Revenue	$ 7,667	$ 6,966
Cost of revenues	5,082	4,209
Gross profit	2,585	2,757
Operating expenses:
Research and development	681	1,110
General and administrative	5,260	3,477
Sales and marketing	1,591	971
Total operating expenses	7,532	5,558
Loss from operations	(4,947)	(2,801)
Other income (expense):
Interest expense	(239)	(194)
Interest income	21	17
Change in fair value of acquisition note payable	17	(232)
Change in fair value of warrant liability	692	(7,294)
Other expense	0	(46)
Total other income (expense)	491	(7,749)
Loss before income taxes	(4,456)	(10,550)
Income tax (benefit)	0	(970)
Net (loss)	$ (4,456)	$ (9,580)
Basic and diluted net (loss) per share (in dollars per share)	$ (0.16)	$ (0.51)
Basic and diluted weighted-average shares outstanding (in shares)	27,049	18,904
Foreign currency translation (loss)	$ (20)	$ 0
Comprehensive (loss)	$ (4,476)	$ (9,580)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss)	$ (4,456)	$ (9,580)
Adjustments to reconcile net (loss) to net cash (used in) operating activities:
Depreciation	429	534
Amortization	135	83
Provision for bad debts	464	(21)
Stock-based compensation	274	435
Change in fair value of acquisition note payable	(17)	232
Change in fair value of warrant liability	(692)	7,294
Amortization of debt issuance costs	0	7
Amortization of discount on debt	0	7
Loss in equity method investment	2	12
Loss on extinguishment of debt	0	78
Changes in:
Accounts receivable	(160)	(901)
Other current assets	(143)	156
Other non-current assets	(5)	28
Accounts payable, accrued expenses and deferred revenue	(279)	(694)
Deferred rent payable and other	(24)	(61)
Net cash (used in) operating activities	(4,472)	(2,391)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets	(221)	(178)
Patent costs	(32)	(31)
Net cash (used in) investing activities	(253)	(209)
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on capital lease obligations	(86)	(34)
Proceeds from warrant exercises	0	1,750
Repayment of borrowings on Silicon Valley Bank line of credit	(627)	0
Proceeds from Partners for Growth IV, L.P. term note	0	6,000
Principal payments on Silicon Valley Bank term note	0	(4,667)
Payment of debt issuance costs and loan fees	0	(287)
Net cash provided by (used in) financing activities	(713)	2,762
Effect of foreign exchange rates on cash and cash equivalents and restricted cash	(32)	0
Net increase (decrease) in cash and cash equivalents and restricted cash	(5,470)	162
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
Beginning	9,891	9,802
Ending	4,421	9,964
SUPPLEMENTAL CASH FLOW DISCLOSURE
Cash paid for interest	245	269
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Fixed assets acquired through capital lease arrangements	150	396
Derivative warrants issued with debt	$ 0	$ 1,004

Organization, Description of Bu

Organization, Description of Business, Basis of Presentation, Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Description of Business, Basis of Presentation, Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements	Organization, Description of Business, Basis of Presentation, Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements We are an emerging leader in the field of precision medicine, enabling individualized therapies in the field of oncology through our tests, services and molecular markers. We develop, commercialize and provide molecular- and biomarker-based tests and services, including proprietary preclinical oncology and immuno-oncology services, that enable biotech and pharmaceutical companies engaged in oncology and immuno-oncology trials to better select candidate populations and reduce adverse drug reactions by providing information regarding genomic and molecular factors influencing subject responses to therapeutics. Through our clinical services, we enable physicians to personalize the clinical management of each individual patient by providing genomic information to better diagnose, monitor and inform cancer treatment. We have a comprehensive, disease-focused oncology testing portfolio, and extensive set of anti-tumor referenced data based on predictive xenograft and syngeneic tumor models. Our tests and techniques target a wide range of indications, covering all ten of the top cancers in prevalence in the United States, with additional unique capabilities offered by our FDA-cleared Tissue of Origin® test for identifying difficult to diagnose tumor types or poorly differentiated metastatic disease. Following the acquisition of vivoPharm, Pty Ltd. (“vivoPharm”) we provide contract research services, focused primarily on unique specialized studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. We were incorporated in the State of Delaware on April 8, 1999 and have offices and state-of-the-art laboratories located in California, New Jersey, North Carolina, Pennsylvania, Australia, and Hyderabad (India). Our laboratories comply with the highest regulatory standards as appropriate for the services we deliver including CLIA, CAP, NY State, California State and NABL (India). Our services are built on a foundation of world-class scientific knowledge and intellectual property in solid and blood-borne cancers, as well as strong academic relationships with major cancer centers such as Memorial Sloan-Kettering, Mayo Clinic, and the National Cancer Institute. We offer preclinical services such as predictive tumor models, human orthotopic xenografts and syngeneic immuno-oncology relevant tumor models in our Hershey PA facility, and a leader in the field of immuno-oncology preclinical services in the United States. This service is supplemented with GLP toxicology and extended bioanalytical services in our Australian based facility in Bundoora VIC. Basis of Presentation The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions for interim reporting as prescribed by the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2017 , filed with the Securities and Exchange Commission on April 2, 2018. The consolidated balance sheet as of December 31, 2017 , included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by GAAP. Interim financial results are not necessarily indicative of the results that may be expected for any future interim period or for the year ending December 31, 2018 . Recently Adopted Accounting Standards Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers.” The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. The ASU replaces most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers: Deferral of the Effective Date” which defers the effective date for ASU 2014-09 by one year. In March 2016, the FASB issued ASU 2016-08, “Principal versus Agent Considerations (Reporting Gross versus Net),” which clarifies the implementation guidance in ASU 2014-09 relating to principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, “Identifying Performance Obligations and Licensing,” which clarifies guidance related to the impact of goods and services on a performance obligation and timing and pattern of recognition issues related to intellectual property contracts. In May 2016, the FASB issued ASU 2016-12, “Narrow-Scope Improvements and Practical Expedients,” which clarifies certain narrow provisions of ASU 2014-09. On January 1, 2018, we adopted these ASUs using the modified retrospective method. We recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of accumulated deficit. Financial information for the three months ended March 31, 2017 has not been restated and continues to be reported under the accounting standards in effect for that period. The transition adjustment resulted in a net reduction to the opening balance of accumulated deficit of $2.5 million on January 1, 2018 and increased deferred revenue associated with Biopharma Services and Discovery Services by $1.9 million and $0.6 million , respectively, due to a change in our policies for recognized revenue for performance obligations fulfilled over time. In our Clinical Services area, the majority of the amounts historically charged as a provision for bad debts are now considered an implicit price concession in determining net revenue under Accounting Standards Codification (“ASC”) Topic 606. Accordingly, we now report uncollectible balances as a reduction in the transaction price, and therefore, as a reduction in net revenues rather than a component of selling, general and administrative expenses. The following table presents the amounts by which each financial statement line item was affected by adopting the new revenue recognition guidance (in thousands): Three Months Ended March 31, 2018 As Reported ASC 606 Adjustments Balances Without Adoption Consolidated Statements of Operations and Other Comprehensive Loss Revenue: Biopharma Services $ 3,658 $ (307 ) 3,351 Clinical Services 2,342 — 2,342 Discovery Services 1,667 (529 ) 1,138 $ 7,667 $ (836 ) $ 6,831 Consolidated Balance Sheets CURRENT LIABILITIES Deferred revenue Biopharma Services $ 1,625 $ (1,547 ) $ 78 Clinical Services — — — Discovery Services 126 (126 ) — $ 1,751 $ (1,673 ) $ 78 NON-CURRENT LIABILITIES Deferred revenue Biopharma Services $ 516 $ — $ 516 Clinical Services — — — Discovery Services 476 — 476 $ 992 $ — $ 992 STOCKHOLDERS' EQUITY Accumulated (deficit) $ (141,799 ) $ 1,673 $ (140,126 ) Restricted Cash Effective January 1, 2018, we adopted ASU 2016-18, which requires companies to include restricted cash accounts with cash and cash equivalents when reconciling the beginning of period and end of period total amounts shown on the consolidated statements of cash flows. Acquisition of vivoPharm On August 15, 2017, we purchased all of the outstanding stock of vivoPharm, with its principal place of business in Victoria, Australia, in a transaction valued at approximately $1.6 million in cash and shares of the Company’s common stock, valued at $8.1 million based on the closing price of the stock on August 15, 2017. The Company has deposited in escrow 20% of the stock consideration until the expiration of twelve months from the closing date to serve as the initial source for any indemnification claims and adjustments. Prior to the acquisition, vivoPharm was a contract research organization (“CRO”) that specialized in planning and conducting unique, specialized studies to guide drug discovery and development programs with a concentration in oncology and immuno-oncology. The transaction is being accounted for using the acquisition method of accounting for business combinations in accordance with GAAP. Under this method, the total consideration transferred to consummate the acquisition is being allocated to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the closing date of the acquisition. The acquisition method of accounting requires extensive use of estimates and judgments to allocate the consideration transferred to the identifiable tangible and intangible assets acquired and liabilities assumed. Accordingly, the allocation of the consideration transferred is preliminary and will be adjusted upon completion of the final valuation of the assets acquired and liabilities assumed. The final valuation is expected to be completed as soon as practicable but no later than twelve months after the closing date of the acquisition. As of March 31, 2018 , the valuation of the lab supplies, deferred revenue and deferred taxes is provisional. The estimated allocation of the purchase price as of August 15, 2017 consists of the following (in thousands): Cash $ 544 Accounts receivable 905 Lab supplies 350 Prepaid expenses and other current assets 60 Fixed assets 765 Intangible assets 3,160 Goodwill 5,960 Accounts payable and accrued expenses (913 ) Deferred revenue (814 ) Deferred rent and other (222 ) Obligations under capital leases (76 ) Total purchase price $ 9,719 The following table provides certain pro forma financial information for the Company as if the acquisition of vivoPharm discussed above occurred on January 1, 2017 (in thousands except per share amounts): Three Months Ended March 31, 2017 Revenue $ 8,134 Net loss (9,795 ) Basic and dilutive net loss per share $ (0.45 ) The results of operations for the three months ended March 31, 2018 include the operations of vivoPharm, which accounted for approximately $1,428,000 of the Company’s consolidated Discovery Services revenue. The net income (loss) of vivoPharm cannot be determined, as its operations were integrated with Cancer Genetics. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. Recent Accounting Pronouncements In February 2016, the FASB issued guidance codified in ASC 842, Leases , which supersedes the guidance in former ASC 840, Leases , to increase transparency and comparability among organizations by requiring recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements. The standard will become effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. The guidance is required to be adopted at the earliest period presented using a modified retrospective approach. We plan to adopt this guidance on the effective date. We are currently evaluating the impact the provisions will have on our consolidated financial statements.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Going Concern At March 31, 2018 , our cash position and history of losses required management to assess our ability to continue operating as a going concern, according to FASB ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The Company does not have sufficient cash at March 31, 2018 to fund normal operations for the next twelve months . In addition, the Company was in violation of certain financial covenants under its debt agreements at December 31, 2017, January 31, 2018, February 28, 2018, March 31, 2018 and April 30, 2018. These covenant violations were waived on May 14, 2018 by SVB and PFG. The Company is in discussions with its lenders to modify the loans and reset the loan covenants, but we can provide no assurances that our current negotiations will be successful. The Company's ability to continue as a going concern is dependent on the Company’s ability to modify its existing debt, raise additional equity or debt capital or spin-off non-core assets to raise additional cash. These factors raise substantial doubt about the Company’s ability to continue as a going concern. We have hired Raymond James & Associates, Inc. as our financial advisor to assist with evaluating strategic options. Such options could include raising more capital, the acquisition of another company and/or complementary assets, the sale of the Company or another type of strategic partnership. We can provide no assurances that our current actions will be successful or that additional sources of financing with be available to us on favorable terms, if at all. The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

Revenue and Accounts Receivable

Revenue and Accounts Receivable	3 Months Ended
	Mar. 31, 2018
Receivables [Abstract]
Revenue and Accounts Receivable	Revenue and Accounts Receivable Revenue by service type for the three months ended March 31, 2018 and 2017 is comprised of the following (in thousands): Three Months Ended March 31, 2018 2017 Biopharma Services 3,658 $ 3,719 Clinical Services 2,342 2,954 Discovery Services 1,667 293 $ 7,667 $ 6,966 The table above includes approximately $1,428,000 of Discovery Services revenue from our acquisition of vivoPharm for the three months ended March 31, 2018 . Accounts receivable by service type at March 31, 2018 and December 31, 2017 consists of the following (in thousands): March 31, December 31, Biopharma Services $ 3,847 $ 3,746 Clinical Services 12,572 12,205 Discovery Services 1,238 1,546 Allowance for doubtful accounts (7,003 ) (6,539 ) $ 10,654 $ 10,958 The table above includes $319,000 of net accounts receivables relating to Discovery Services that are included in assets held for sale on the Consolidated Balance Sheet as of March 31, 2018 . Revenue for Biopharma Services are customized solutions for patient stratification and treatment selection through an extensive suite of DNA-based testing services. Biopharma Services are billed to pharmaceutical and biotechnology companies. Clinical Services are tests performed to provide information on diagnosis of cancers to guide patient management. Clinical Services tests can be billed to Medicare, another third party insurer or the referring community hospital or other healthcare facility, or directly to patients. Discovery Services are services that provide the tools and testing methods for companies and researchers seeking to identify new DNA-based biomarkers for disease. The breakdown of our Clinical Services revenue (as a percent of total revenue) is as follows: Three Months Ended March 31, 2018 2017 Medicare 9% 14% Other insurers 16% 23% Other healthcare facilities 5% 6% 30% 43% We have historically derived a significant portion of our revenue from a limited number of test ordering sites. Test ordering sites account for all of our Clinical Services revenue. Our test ordering sites are largely hospitals, cancer centers, reference laboratories, physician offices and biopharmaceutical companies. Oncologists and pathologists at these sites order the tests on behalf of the needs of their oncology patients or as part of a clinical trial sponsored by a biopharmaceutical company in which the patient is being enrolled. We generally do not have formal, long-term written agreements with such test ordering sites, and, as a result, we may lose a significant test ordering site at any time, except with biopharmaceutical companies. The top five test ordering sites during the three months ended March 31, 2018 and 2017 accounted for approximately 17% and 35% of our testing volumes, respectively. During the three months ended March 31, 2018 , there were no customers that accounted for more than 10% of our total revenue. During the three months ended March 31, 2017 , there was one biopharmaceutical company which accounted for approximately 11% of our total revenue. We record deferred revenues (contract liabilities) when cash payments are received or due in advance of our performance, including amounts which are refundable. Performance Obligations : Biopharma Services Clinical Services Discovery Services Performance Obligation Satisfaction and Revenue Recognition: Performance obligations are satisfied at a point in time as the Company processes samples delivered by the customer. Project level activities, including study setup and project management, are satisfied over the life of the contract. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer. Project level fee revenue is recognized ratably over the life of the contract. Performance obligations are satisfied at a point in time when the tests are reported to the customer. Revenues are recognized at a point in time when the test results are reported to the ordering site. Performance obligations are satisfied over time and revenue is recognized using the time elapsed method as the Company delivers study results to the customers. Significant Payment Terms: Monthly invoices at a contractual rate are generated as services are delivered for work completed during the prior month. Some contracts have prepayments prior to services being rendered that are recorded as deferred revenue. The Company invoices at its list price or contractually negotiated price. Payments realized vary from amounts invoiced. Accordingly, the Company estimates the variable consideration it expects to collect. As results are delivered, the invoices are generated based on contractual rates. Some contracts have prepayments prior to services being rendered that are recorded as deferred revenue. Nature of Services: Biopharma testing services, study setup and study management Clinical testing services Discovery services Remaining Performance Obligations : Services offered under the Biopharma and Discovery Services frequently take time to complete under their respective contacts. These times vary depending on specific contract arrangements like the length of the study in the case of Discovery Services and how samples are delivered to us for processing in the case of Biopharma Services. In the case of Clinical Services and Discovery Services, the duration of performance obligation is less than one year . As of March 31, 2018 the Company had $27.4 million in remaining performance obligations in the Biopharma Services area. We expect to recognize the remaining performance obligations over the next two years . Practical Expedients : Our customer arrangements in Biopharma Services and Discovery Services do not contain any significant financing component (interest). We have not recognized the financing component in the case of Clinical Services, as the payment plans we may grant to our self-pay customers do not to exceed six months . We do not incur any incremental costs to obtain or fulfill our customer contracts that require capitalization under the new revenue standard and have elected the practical expedient afforded by the new revenue standard to expense such costs as incurred. We exclude from the measurement of the transaction price all taxes that we collect from customers that are assessed by governmental authorities and are both imposed on and concurrent with specific revenue-producing transactions.

Assets and Liabilities Held for

Assets and Liabilities Held for Sale	3 Months Ended
	Mar. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities Held for Sale	Assets and Liabilities Held for Sale On March 22, 2018, our Board of Directors unanimously approved a plan to sell our India subsidiary, BioServe Biotechnologies (India) Private Limited to Reprocell, Inc., for cash consideration of $1.5 million to $2.0 million in the next 30 to 45 days . On April 26, 2018, the sale closed for an all cash purchase price of $1.9 million , subject to downward adjustment of up to $300,000 , based on a formula set forth in the purchase agreement, if the India subsidiary does not meet the specified revenue target. At March 31, 2018 , the assets and liabilities of the India subsidiary have been presented as being held for sale in our Consolidated Balance Sheets. The carrying value of the assets and liabilities held for sale of our India subsidiary approximates the fair value on March 31, 2018 . Assets and liabilities held for sale consist of the following at March 31, 2018 : Current assets held for sale: Cash and cash equivalents $ 49 Accounts receivable, net 319 Other current assets 228 Fixed assets, net 628 Goodwill 735 Other 99 Total current assets held for sale $ 2,058 Current liabilities held for sale: Accounts payable and accrued expenses $ 209 Deferred rent and other 12 Total current liabilities held for sale $ 221

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share For purposes of this calculation, stock warrants, outstanding stock options and unvested restricted shares are considered common stock equivalents using the treasury stock method, and are the only such equivalents outstanding. For the three months ended March 31, 2018 and 2017, all common stock equivalents outstanding were anti-dilutive. The following table summarizes equivalent units outstanding that were excluded from the earnings per share calculation because their effects were anti-dilutive (in thousands): Three Months Ended March 31, 2018 2017 Common stock purchase warrants 10,055 6,608 Stock options 2,534 2,520 Restricted shares of common stock 683 68 13,272 9,196

Term Note and Line of Credit

Term Note and Line of Credit	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Term Note and Line of Credit	Term Note and Line of Credit On March 22, 2017, we entered into a two year asset-based revolving line of credit agreement with Silicon Valley Bank (“SVB”). The SVB credit facility provides for an asset-based line of credit (“ABL”) for an amount not to exceed the lesser of (a) $6.0 million or (b) 80% of eligible accounts receivable plus the lesser of 50% of the net collectible value of third party accounts receivable or three ( 3 ) times the average monthly collection amount of third party accounts receivable over the previous quarter. The ABL requires monthly interest payments at the Wall Street Journal prime rate plus 1.50% ( 6.25% at March 31, 2018 ) and matures on March 22, 2019. We also pay a fee of 0.25% per year on the average unused portion of the ABL. At March 31, 2018 , we have borrowed $3.5 million on the ABL, which is the maximum amount allowed based on eligible accounts receivable. We concurrently entered into a three year $6.0 million term loan agreement (“PFG Term Note”) with Partners for Growth IV, L.P. (“PFG”). The PFG Term Note is an interest only loan with the full principal and any outstanding interest due at maturity on March 22, 2020. Interest is payable monthly at a rate of 11.5% per annum, with the possibility of reducing to 11.0% in 2018 based on achieving certain financial milestones set forth by PFG. We may prepay the PFG Term Note in whole or part at any time without penalty. Both loan agreements require us to comply with certain financial covenants, including minimum adjusted EBITDA, revenue and liquidity covenants, and restrict us from, among other things, paying cash dividends, incurring debt and entering into certain transactions without the prior consent of the lenders. Repayment of amounts borrowed under the new loan agreements may be accelerated if an event of default occurs, which includes, among other things, a violation of such financial covenants and negative covenants. As of December 31, 2017, January 31, 2018, February 28, 2018, March 31, 2018 and April 30, 2018, we were in violation of certain financial covenants. These covenant violations were waived on May 14, 2018 by SVB and PFG. The Company is in discussions with its lenders to modify the loans and reset the loan covenants. Our obligations to SVB under the ABL facility are secured by a first priority security interest on substantially all of our assets, and our obligations under the PFG Term Note are secured by a second priority security interest subordinated to the SVB lien. In connection with the PFG Term Note, we issued seven year warrants to the lenders to purchase an aggregate of 443,262 shares of our common stock at an exercise price of $2.82 per share (the “PFG Warrants”). At March 31, 2018 , the principal amount of the PFG Term Note of $6,000,000 is due in 2020. Even though we received loan covenant waivers through April 30, 2018, future anticipated violations under the existing agreements and the requirement to raise capital requires us to present the PFG Term Note as a current liability.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation We have two equity incentive plans: the 2008 Stock Option Plan (the “2008 Plan”) and the 2011 Equity Incentive Plan (the “2011 Plan”, and together with the 2008 Plan, the “Stock Option Plans”). The Stock Option Plans are meant to provide additional incentive to officers, employees and consultants to remain in our employment. Options granted are generally exercisable for up to 10 years . At March 31, 2018 , 693,161 shares remain available for future awards under the 2011 Plan and 134,546 shares remain available for future awards under the 2008 Plan. Effective April 9, 2018, the Company is no longer able to issue options from the 2008 Plan. A summary of employee and non-employee stock option activity for the three months ended March 31, 2018 is as follows: Options Outstanding Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Number of Shares (in thousands) Weighted- Average Exercise Price Outstanding January 1, 2018 2,844 $ 7.00 6.96 $ 4 Cancelled or expired (310 ) 5.13 Outstanding March 31, 2018 2,534 $ 7.23 5.70 $ — Exercisable March 31, 2018 1,749 $ 9.02 4.30 $ — On May 10, 2018, the Company granted employees options to purchase 661,000 shares of the Company’s common stock, including 350,000 options granted to our Chief Executive Officer, which are subject to certain performance conditions, as discussed in Note 14. The options have an exercise price of $0.89 per share and vest over a period of 5 years . Aggregate intrinsic value represents the difference between the fair value of our common stock and the exercise price of outstanding, in-the-money options. As of March 31, 2018 , total unrecognized compensation cost related to non-vested stock options granted to employees was $1,463,020 which we expect to recognize over the next 2.28 years. The fair value of options granted to employees is estimated on the grant date using the Black-Scholes option valuation model. This valuation model requires us to make assumptions and judgments about the variables used in the calculation, including the expected term (the period of time that the options granted are expected to be outstanding), the volatility of our common stock, a risk-free interest rate, and expected dividends. Forfeitures will be recorded when they occur. No compensation cost is recorded for options that do not vest. We use the simplified calculation of expected life described in the SEC’s Staff Accounting Bulletin No. 107, Share-Based Payment , and volatility is based on the historical volatility of our common stock. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. We use an expected dividend yield of zero , as we do not anticipate paying any dividends in the foreseeable future. The following table presents the weighted-average assumptions used to estimate the fair value of options granted to employees during the periods presented: Three Months Ended March 31, 2017 Volatility 73.57 % Risk free interest rate 2.03 % Dividend yield 0.00 % Term (years) 6.00 Weighted-average fair value of options granted during the period 1.63 In May 2014, we issued 200,000 options to a Director with an exercise price of $15.89 . See Note 12 for additional information. The following table presents the weighted-average assumptions used to estimate the fair value of options reaching their measurement date for non-employees during the periods presented: Three Months Ended March 31, 2017 Volatility 77.41 % Risk free interest rate 2.22 % Dividend yield 0.00 % Term (years) 7.14 Restricted stock awards have been granted to employees, directors and consultants as compensation for services. At March 31, 2018 , there was $155,911 of unrecognized compensation cost related to non-vested restricted stock granted to employees and directors; we expect to recognize the cost over 1.29 years. The following table summarizes the activities for our non-vested restricted stock awards for the three months ended March 31, 2018 : Non-vested Restricted Stock Awards Number of Weighted-Average Grant Date Fair Value Non-vested at January 1, 2018 91 $ 4.21 Vested (2 ) 6.30 Cancelled (20 ) $ 6.50 Non-vested at March 31, 2018 69 $ 3.48 The following table presents the effects of stock-based compensation related to stock option and restricted stock awards to employees and non-employees on our Consolidated Statements of Operations and Other Comprehensive Loss during the periods presented (in thousands): Three Months Ended March 31, 2018 2017 Cost of revenues $ 91 $ 59 Research and development 15 50 General and administrative 158 300 Sales and marketing 10 26 Total stock-based compensation $ 274 $ 435

Warrants

Warrants	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Warrants	Warrants There was no warrant activity during the three months ended March 31, 2018 . The following table presents warrants outstanding at March 31, 2018 (in thousands, except exercise price): Issued With / For Exercise Warrants Outstanding March 31, 2018 Non-Derivative Warrants: Financing $ 10.00 243 Financing 15.00 276 2015 Offering 5.00 3,450 Total non-derivative warrants $ 6.00 C 3,969 Derivative Warrants: 2016 Offerings 2.25 A 1,968 2017 Debt 2.82 B 443 2017 Offering 2.35 A 3,500 2017 Offering 2.50 A 175 Total derivative warrants 2.36 C 6,086 Total $ 3.80 C 10,055 A These warrants are subject to fair value accounting and contain a contingent net cash settlement feature. See Note 9. B These warrants are subject to fair value accounting until the number of shares issuable upon the exercise of the warrants becomes fixed. See Note 9. C Weighted-average exercise prices are as of March 31, 2018 .

Fair Value of Warrants

Fair Value of Warrants	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value of Warrants	Fair Value of Warrants The following table summarizes the derivative warrant activity subject to fair value accounting for the three months ended March 31, 2018 (in thousands): Issued with/for Fair value of warrants Change in fair Fair value of warrants 2016 Offerings $ 1,929 $ 27 $ 1,956 2017 Debt 501 (78 ) 423 2017 Offering 1,973 (641 ) 1,332 $ 4,403 $ (692 ) $ 3,711 The derivative warrants issued as part of the 2016 Offerings are valued using a probability-weighted Binomial model, while the derivative warrants issued as part of the 2017 Debt refinancing are valued using a Monte Carlo model. The derivative warrants issued in conjunction with the 2017 Offering were valued using a Black-Scholes model. The following tables summarize the assumptions used in computing the fair value of derivative warrants subject to fair value accounting at the date of issue or exercise during the three months ended March 31, 2018 and 2017 , and at March 31, 2018 and December 31, 2017 . 2016 Offerings As of March 31, 2018 As of December 31, 2017 Exercised During the Three Months Ended March 31, 2017 Exercise price $ 2.25 $ 2.25 $ 2.25 Expected life (years) 3.83 4.08 4.79 Expected volatility 100.00 % 73.44 % 76.29 % Risk-free interest rate 2.39 % 2.11 % 1.94 % Expected dividend yield — % — % — % 2017 Debt As of March 31, 2018 As of December 31, 2017 Issued During the Three Months Ended March 31, 2017 Exercise price $ 2.82 $ 2.82 $ 2.82 Expected life (years) 5.98 6.22 7.00 Expected volatility 73.43 % 74.18 % 74.61 % Risk-free interest rate 2.56 % 2.33 % 2.22 % Expected dividend yield — % — % — % 2017 Offering As of March 31, 2018 As of December 31, 2017 Exercise price $ 2.36 2.36 Expected life (years) 1.19 1.43 Expected volatility 76.78 % 77.55 % Risk-free interest rate 2.09 % 1.83 % Expected dividend yield — % — %

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Fair Value Measurements and Disclosures Topic of the FASB ASC requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. Inputs to valuation techniques refer to the assumptions that market participants would use in pricing the asset or liability. Inputs may be observable, meaning those that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from independent sources, or unobservable, meaning those that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. In that regard, the Topic establishes a fair value hierarchy for valuation inputs that give the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that we have the ability to access as of the measurement date. Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. Level 3: Significant unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing an asset or liability. The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value (in thousands): March 31, 2018 Total Quoted Prices in Significant Other Significant Warrant liability $ 3,711 $ — $ — $ 3,711 Note payable 139 — — 139 $ 3,850 $ — $ — $ 3,850 December 31, 2017 Total Quoted Prices in Significant Other Significant Warrant liability $ 4,403 $ — $ — $ 4,403 Note payable 156 — — 156 $ 4,559 $ — $ — $ 4,559 At March 31, 2018 and December 31, 2017 , the Company had a note payable to VenturEast from a prior acquisition. The ultimate payment to VenturEast will be the fair value of 84,278 shares of our common stock at the time of payment. During the three months ended March 31, 2018 and 2017 , we recognized a gain of approximately $17,000 and a loss of approximately $232,000 , respectively, due to changes in our stock price. At March 31, 2018 , the warrant liability consists of stock warrants issued as part of the 2016 Offerings and 2017 Offering that contain contingent redemption features and warrants issued as part of the 2017 debt refinancing. In accordance with derivative accounting for warrants, we calculated the fair value of warrants and the assumptions used are described in Note 9, “Fair Value of Warrants.” During the three months ended March 31, 2018 , we recognized a gain of approximately $692,000 on the derivative warrants due to changes in our stock price. During the three months ended March 31, 2017 , we recorded a loss of approximately $7,294,000 on the derivative warrants due to changes in our stock price. Realized and unrealized gains and losses related to the change in fair value of the VenturEast note and warrant liability are included in other income (expense) on the Consolidated Statements of Operations and Other Comprehensive Loss. The following table summarizes the activity of the note payable to VenturEast and of our derivative warrants, which was measured at fair value using Level 3 inputs (in thousands): Note Payable Warrant to VenturEast Liability Fair value at December 31, 2017 $ 156 $ 4,403 Change in fair value (17 ) (692 ) Fair value at March 31, 2018 $ 139 $ 3,711

Joint Venture Agreement

Joint Venture Agreement	3 Months Ended
	Mar. 31, 2018
Equity Method Investments and Joint Ventures [Abstract]
Joint Venture Agreement	Joint Venture Agreement In November 2011 , we entered into an affiliation agreement with the Mayo Foundation for Medical Education and Research (“Mayo”), subsequently amended. Under the agreement, we formed a joint venture with Mayo in May 2013 to focus on developing oncology diagnostic services and tests utilizing next generation sequencing. The joint venture is a limited liability company, with each party initially holding fifty percent of the issued and outstanding membership interests of the new entity (the “JV”). The agreement requires aggregate capital contributions by us of up to $6.0 million , of which $2.0 million has been paid to date. The timing of the remaining installments is subject to the JV's achievement of certain operational milestones agreed upon by the board of governors of the JV. In exchange for its membership interest, Mayo’s capital contribution takes the form of cash, staff, services, hardware and software resources, laboratory space and instrumentation, the fair market value of which will be approximately equal to $6.0 million . Mayo’s continued contribution will also be conditioned upon the JV’s achievement of certain milestones. Our share of the JV’s net loss was approximately $2,000 and $12,000 for the three months ended March 31, 2018 and 2017 , respectively, and is included in research and development expense on the Consolidated Statements of Operations. We have a net receivable due from the JV of approximately $10,000 at March 31, 2018 , which is included in other assets in the Consolidated Balance Sheets. The joint venture is considered a variable interest entity under ASC 810-10, but we are not the primary beneficiary as we do not have the power to direct the activities of the JV that most significantly impact its performance. Our evaluation of ability to impact performance is based on our equal board membership and voting rights and day-to-day management functions which are performed by the Mayo personnel.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions We have a consulting agreement with Equity Dynamics, Inc. (“EDI”), an entity controlled by John Pappajohn, effective April 1, 2014 pursuant to which EDI receives a monthly fee of $10,000 . Total expenses for each of the three months ended March 31, 2018 and 2017 were $30,000 . As of March 31, 2018 , we owed EDI $20,000 . Pursuant to a consulting and advisory agreement that ended December 31, 2016, Dr. Chaganti received an option to purchase 200,000 shares of our common stock at a purchase price of $15.89 per share vesting over a period of four years. Total non-cash stock-based compensation recognized under the consulting agreement for the three months ended March 31, 2018 and 2017 was $0 and $25,625 , respectively.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies On April 5, 2018 and April 12, 2018, purported stockholders of the Company filed nearly identical putative class action lawsuits in the U.S. District Court for the District of New Jersey, against the Company, Panna L. Sharma, John A. Roberts, and Igor Gitelman, captioned Ben Phetteplace v. Cancer Genetics, Inc. et al. , No. 2:18-cv-05612 and Ruo Fen Zhang v. Cancer Genetics, Inc. et al ., No. 2:18-06353, respectively. The complaints allege violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 based on allegedly false and misleading statements and omissions regarding our business, operational, and financial results. The lawsuits seek, among other things, unspecified compensatory damages in connection with purchases of our stock between March 23, 2017 and April 2, 2018, as well as interest, attorneys’ fees, and costs. The Company is unable to predict the ultimate outcome of these actions and therefore cannot estimate possible losses or ranges of losses, if any.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On April 26, 2018, we entered into a share purchase agreement with Reprocell Incorporated pursuant to which the Company sold its shares in its India subsidiary in an all cash transaction. The purchase price was $1.9 million , subject to downward adjustment by up to $300,000 , based on a formula set forth in the purchase agreement, if the India subsidiary does not meet the specified revenue target. Effective April 30, 2018, John A. Roberts was promoted to Chief Executive Officer and President of the Company. On May 10, 2018, the Board of Directors increased Mr. Roberts’ salary to $350,000 per year and approved an award of 350,000 options to purchase common stock to Mr. Roberts, with the vesting of such options subject to satisfaction of certain performance conditions consistent with the Company’s current business plan and time vesting. On May 14, 2018, the Company received waivers from its senior lenders for its failure to comply with certain financial covenants for the months of December 31, 2017, January 31, 2018, February 28, 2018, March 31, 2018 and April 30, 2018. The Company concurrently amended its debt agreements with SVB and PFG, respectively; the new agreements require the Company to raise $2,500,000 from the sale of its equity securities or the issuance of subordinated debt (in the case of the agreement with SVB, to investors acceptable to SVB) by June 30, 2018. In addition, as a condition of the waiver by PFG, the Company anticipates entering into an amendment to the PFG Warrants to reduce the exercise price thereof.

Organization, Description of 20

Organization, Description of Business, Basis of Presentation, Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements (Policies)	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions for interim reporting as prescribed by the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2017 , filed with the Securities and Exchange Commission on April 2, 2018. The consolidated balance sheet as of December 31, 2017 , included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by GAAP. Interim financial results are not necessarily indicative of the results that may be expected for any future interim period or for the year ending December 31, 2018 .
Acquisitions	The transaction is being accounted for using the acquisition method of accounting for business combinations in accordance with GAAP. Under this method, the total consideration transferred to consummate the acquisition is being allocated to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the closing date of the acquisition. The acquisition method of accounting requires extensive use of estimates and judgments to allocate the consideration transferred to the identifiable tangible and intangible assets acquired and liabilities assumed.
Recently Adopted Accounting Standards and Recent Accounting Pronouncements	Recently Adopted Accounting Standards Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers.” The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. The ASU replaces most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers: Deferral of the Effective Date” which defers the effective date for ASU 2014-09 by one year. In March 2016, the FASB issued ASU 2016-08, “Principal versus Agent Considerations (Reporting Gross versus Net),” which clarifies the implementation guidance in ASU 2014-09 relating to principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, “Identifying Performance Obligations and Licensing,” which clarifies guidance related to the impact of goods and services on a performance obligation and timing and pattern of recognition issues related to intellectual property contracts. In May 2016, the FASB issued ASU 2016-12, “Narrow-Scope Improvements and Practical Expedients,” which clarifies certain narrow provisions of ASU 2014-09. On January 1, 2018, we adopted these ASUs using the modified retrospective method. We recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of accumulated deficit. Financial information for the three months ended March 31, 2017 has not been restated and continues to be reported under the accounting standards in effect for that period. The transition adjustment resulted in a net reduction to the opening balance of accumulated deficit of $2.5 million on January 1, 2018 and increased deferred revenue associated with Biopharma Services and Discovery Services by $1.9 million and $0.6 million , respectively, due to a change in our policies for recognized revenue for performance obligations fulfilled over time. In our Clinical Services area, the majority of the amounts historically charged as a provision for bad debts are now considered an implicit price concession in determining net revenue under Accounting Standards Codification (“ASC”) Topic 606. Accordingly, we now report uncollectible balances as a reduction in the transaction price, and therefore, as a reduction in net revenues rather than a component of selling, general and administrative expenses. The following table presents the amounts by which each financial statement line item was affected by adopting the new revenue recognition guidance (in thousands): Three Months Ended March 31, 2018 As Reported ASC 606 Adjustments Balances Without Adoption Consolidated Statements of Operations and Other Comprehensive Loss Revenue: Biopharma Services $ 3,658 $ (307 ) 3,351 Clinical Services 2,342 — 2,342 Discovery Services 1,667 (529 ) 1,138 $ 7,667 $ (836 ) $ 6,831 Consolidated Balance Sheets CURRENT LIABILITIES Deferred revenue Biopharma Services $ 1,625 $ (1,547 ) $ 78 Clinical Services — — — Discovery Services 126 (126 ) — $ 1,751 $ (1,673 ) $ 78 NON-CURRENT LIABILITIES Deferred revenue Biopharma Services $ 516 $ — $ 516 Clinical Services — — — Discovery Services 476 — 476 $ 992 $ — $ 992 STOCKHOLDERS' EQUITY Accumulated (deficit) $ (141,799 ) $ 1,673 $ (140,126 ) Restricted Cash Effective January 1, 2018, we adopted ASU 2016-18, which requires companies to include restricted cash accounts with cash and cash equivalents when reconciling the beginning of period and end of period total amounts shown on the consolidated statements of cash flows. Recent Accounting Pronouncements In February 2016, the FASB issued guidance codified in ASC 842, Leases , which supersedes the guidance in former ASC 840, Leases , to increase transparency and comparability among organizations by requiring recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements. The standard will become effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. The guidance is required to be adopted at the earliest period presented using a modified retrospective approach. We plan to adopt this guidance on the effective date. We are currently evaluating the impact the provisions will have on our consolidated financial statements.
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation.

Organization, Description of 21

Organization, Description of Business, Basis of Presentation, Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements (Tables)	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Financial Statement Line Items Affected by Adoption of New Revenue Recognition Guidance	The following table presents the amounts by which each financial statement line item was affected by adopting the new revenue recognition guidance (in thousands): Three Months Ended March 31, 2018 As Reported ASC 606 Adjustments Balances Without Adoption Consolidated Statements of Operations and Other Comprehensive Loss Revenue: Biopharma Services $ 3,658 $ (307 ) 3,351 Clinical Services 2,342 — 2,342 Discovery Services 1,667 (529 ) 1,138 $ 7,667 $ (836 ) $ 6,831 Consolidated Balance Sheets CURRENT LIABILITIES Deferred revenue Biopharma Services $ 1,625 $ (1,547 ) $ 78 Clinical Services — — — Discovery Services 126 (126 ) — $ 1,751 $ (1,673 ) $ 78 NON-CURRENT LIABILITIES Deferred revenue Biopharma Services $ 516 $ — $ 516 Clinical Services — — — Discovery Services 476 — 476 $ 992 $ — $ 992 STOCKHOLDERS' EQUITY Accumulated (deficit) $ (141,799 ) $ 1,673 $ (140,126 )
Assets and Liabilities Acquired in Business Acquisition	The estimated allocation of the purchase price as of August 15, 2017 consists of the following (in thousands): Cash $ 544 Accounts receivable 905 Lab supplies 350 Prepaid expenses and other current assets 60 Fixed assets 765 Intangible assets 3,160 Goodwill 5,960 Accounts payable and accrued expenses (913 ) Deferred revenue (814 ) Deferred rent and other (222 ) Obligations under capital leases (76 ) Total purchase price $ 9,719
Business Acquisition, Pro Forma Information	The following table provides certain pro forma financial information for the Company as if the acquisition of vivoPharm discussed above occurred on January 1, 2017 (in thousands except per share amounts): Three Months Ended March 31, 2017 Revenue $ 8,134 Net loss (9,795 ) Basic and dilutive net loss per share $ (0.45 )

Revenue and Accounts Receivab22

Revenue and Accounts Receivable (Tables)	3 Months Ended
	Mar. 31, 2018
Receivables [Abstract]
Schedule of revenue by service type	Revenue by service type for the three months ended March 31, 2018 and 2017 is comprised of the following (in thousands): Three Months Ended March 31, 2018 2017 Biopharma Services 3,658 $ 3,719 Clinical Services 2,342 2,954 Discovery Services 1,667 293 $ 7,667 $ 6,966
Schedule of accounts receivable by service type	Accounts receivable by service type at March 31, 2018 and December 31, 2017 consists of the following (in thousands): March 31, December 31, Biopharma Services $ 3,847 $ 3,746 Clinical Services 12,572 12,205 Discovery Services 1,238 1,546 Allowance for doubtful accounts (7,003 ) (6,539 ) $ 10,654 $ 10,958
Schedule of clinical services revenue (as a percent of total revenue)	The breakdown of our Clinical Services revenue (as a percent of total revenue) is as follows: Three Months Ended March 31, 2018 2017 Medicare 9% 14% Other insurers 16% 23% Other healthcare facilities 5% 6% 30% 43%
Schedule of description of remaining performance obligation terms	Performance Obligations : Biopharma Services Clinical Services Discovery Services Performance Obligation Satisfaction and Revenue Recognition: Performance obligations are satisfied at a point in time as the Company processes samples delivered by the customer. Project level activities, including study setup and project management, are satisfied over the life of the contract. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer. Project level fee revenue is recognized ratably over the life of the contract. Performance obligations are satisfied at a point in time when the tests are reported to the customer. Revenues are recognized at a point in time when the test results are reported to the ordering site. Performance obligations are satisfied over time and revenue is recognized using the time elapsed method as the Company delivers study results to the customers. Significant Payment Terms: Monthly invoices at a contractual rate are generated as services are delivered for work completed during the prior month. Some contracts have prepayments prior to services being rendered that are recorded as deferred revenue. The Company invoices at its list price or contractually negotiated price. Payments realized vary from amounts invoiced. Accordingly, the Company estimates the variable consideration it expects to collect. As results are delivered, the invoices are generated based on contractual rates. Some contracts have prepayments prior to services being rendered that are recorded as deferred revenue. Nature of Services: Biopharma testing services, study setup and study management Clinical testing services Discovery services

Assets and Liabilities Held f23

Assets and Liabilities Held for Sale (Tables)	3 Months Ended
	Mar. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Schedule of assets and liabilities held for sale	Assets and liabilities held for sale consist of the following at March 31, 2018 : Current assets held for sale: Cash and cash equivalents $ 49 Accounts receivable, net 319 Other current assets 228 Fixed assets, net 628 Goodwill 735 Other 99 Total current assets held for sale $ 2,058 Current liabilities held for sale: Accounts payable and accrued expenses $ 209 Deferred rent and other 12 Total current liabilities held for sale $ 221

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Summary of anti-dilutive equivalent units outstanding excluded from earnings per share calculation	The following table summarizes equivalent units outstanding that were excluded from the earnings per share calculation because their effects were anti-dilutive (in thousands): Three Months Ended March 31, 2018 2017 Common stock purchase warrants 10,055 6,608 Stock options 2,534 2,520 Restricted shares of common stock 683 68 13,272 9,196

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of employee and nonemployee stock option activity	A summary of employee and non-employee stock option activity for the three months ended March 31, 2018 is as follows: Options Outstanding Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Number of Shares (in thousands) Weighted- Average Exercise Price Outstanding January 1, 2018 2,844 $ 7.00 6.96 $ 4 Cancelled or expired (310 ) 5.13 Outstanding March 31, 2018 2,534 $ 7.23 5.70 $ — Exercisable March 31, 2018 1,749 $ 9.02 4.30 $ —
Weighted-average assumptions used to estimate fair value of options granted	The following table presents the weighted-average assumptions used to estimate the fair value of options reaching their measurement date for non-employees during the periods presented: Three Months Ended March 31, 2017 Volatility 77.41 % Risk free interest rate 2.22 % Dividend yield 0.00 % Term (years) 7.14 The following table presents the weighted-average assumptions used to estimate the fair value of options granted to employees during the periods presented: Three Months Ended March 31, 2017 Volatility 73.57 % Risk free interest rate 2.03 % Dividend yield 0.00 % Term (years) 6.00 Weighted-average fair value of options granted during the period 1.63
Nonvested restricted stock shares activity	The following table summarizes the activities for our non-vested restricted stock awards for the three months ended March 31, 2018 : Non-vested Restricted Stock Awards Number of Weighted-Average Grant Date Fair Value Non-vested at January 1, 2018 91 $ 4.21 Vested (2 ) 6.30 Cancelled (20 ) $ 6.50 Non-vested at March 31, 2018 69 $ 3.48
Effects of stock-based compensation related to stock option and restricted stock awards	The following table presents the effects of stock-based compensation related to stock option and restricted stock awards to employees and non-employees on our Consolidated Statements of Operations and Other Comprehensive Loss during the periods presented (in thousands): Three Months Ended March 31, 2018 2017 Cost of revenues $ 91 $ 59 Research and development 15 50 General and administrative 158 300 Sales and marketing 10 26 Total stock-based compensation $ 274 $ 435

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Summary of warrant activity	The following table presents warrants outstanding at March 31, 2018 (in thousands, except exercise price): Issued With / For Exercise Warrants Outstanding March 31, 2018 Non-Derivative Warrants: Financing $ 10.00 243 Financing 15.00 276 2015 Offering 5.00 3,450 Total non-derivative warrants $ 6.00 C 3,969 Derivative Warrants: 2016 Offerings 2.25 A 1,968 2017 Debt 2.82 B 443 2017 Offering 2.35 A 3,500 2017 Offering 2.50 A 175 Total derivative warrants 2.36 C 6,086 Total $ 3.80 C 10,055 A These warrants are subject to fair value accounting and contain a contingent net cash settlement feature. See Note 9. B These warrants are subject to fair value accounting until the number of shares issuable upon the exercise of the warrants becomes fixed. See Note 9. C Weighted-average exercise prices are as of March 31, 2018 .

Fair Value of Warrants (Tables)

Fair Value of Warrants (Tables)	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Schedule of derivative warrant liability	The following table summarizes the derivative warrant activity subject to fair value accounting for the three months ended March 31, 2018 (in thousands): Issued with/for Fair value of warrants Change in fair Fair value of warrants 2016 Offerings $ 1,929 $ 27 $ 1,956 2017 Debt 501 (78 ) 423 2017 Offering 1,973 (641 ) 1,332 $ 4,403 $ (692 ) $ 3,711
Assumptions used in computing fair value of derivative warrants	The following tables summarize the assumptions used in computing the fair value of derivative warrants subject to fair value accounting at the date of issue or exercise during the three months ended March 31, 2018 and 2017 , and at March 31, 2018 and December 31, 2017 . 2016 Offerings As of March 31, 2018 As of December 31, 2017 Exercised During the Three Months Ended March 31, 2017 Exercise price $ 2.25 $ 2.25 $ 2.25 Expected life (years) 3.83 4.08 4.79 Expected volatility 100.00 % 73.44 % 76.29 % Risk-free interest rate 2.39 % 2.11 % 1.94 % Expected dividend yield — % — % — % 2017 Debt As of March 31, 2018 As of December 31, 2017 Issued During the Three Months Ended March 31, 2017 Exercise price $ 2.82 $ 2.82 $ 2.82 Expected life (years) 5.98 6.22 7.00 Expected volatility 73.43 % 74.18 % 74.61 % Risk-free interest rate 2.56 % 2.33 % 2.22 % Expected dividend yield — % — % — % 2017 Offering As of March 31, 2018 As of December 31, 2017 Exercise price $ 2.36 2.36 Expected life (years) 1.19 1.43 Expected volatility 76.78 % 77.55 % Risk-free interest rate 2.09 % 1.83 % Expected dividend yield — % — %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Summary of financial liabilities measured at fair value on a recurring basis	The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value (in thousands): March 31, 2018 Total Quoted Prices in Significant Other Significant Warrant liability $ 3,711 $ — $ — $ 3,711 Note payable 139 — — 139 $ 3,850 $ — $ — $ 3,850 December 31, 2017 Total Quoted Prices in Significant Other Significant Warrant liability $ 4,403 $ — $ — $ 4,403 Note payable 156 — — 156 $ 4,559 $ — $ — $ 4,559
Schedule of fair value notes payable of business acquisition and warrant liability	The following table summarizes the activity of the note payable to VenturEast and of our derivative warrants, which was measured at fair value using Level 3 inputs (in thousands): Note Payable Warrant to VenturEast Liability Fair value at December 31, 2017 $ 156 $ 4,403 Change in fair value (17 ) (692 ) Fair value at March 31, 2018 $ 139 $ 3,711

Organization, Description of 29

Organization, Description of Business, Basis of Presentation, Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements - Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Jan. 01, 2018	Dec. 31, 2017
Consolidated Statements of Operations and Other Comprehensive Loss
Revenue	$ 7,667	$ 6,966
CURRENT LIABILITIES
Deferred revenue	1,751			$ 516
NON-CURRENT LIABILITIES
Deferred revenue, long-term	992			429
STOCKHOLDERS’ EQUITY
Accumulated (deficit)	(141,799)			$ (134,834)
Biopharma Services
Consolidated Statements of Operations and Other Comprehensive Loss
Revenue	3,658	3,719
CURRENT LIABILITIES
Deferred revenue	1,625
NON-CURRENT LIABILITIES
Deferred revenue, long-term	516
Clinical Services
Consolidated Statements of Operations and Other Comprehensive Loss
Revenue	2,342	2,954
CURRENT LIABILITIES
Deferred revenue	0
NON-CURRENT LIABILITIES
Deferred revenue, long-term	0
Discovery Services
Consolidated Statements of Operations and Other Comprehensive Loss
Revenue	1,667	$ 293
CURRENT LIABILITIES
Deferred revenue	126
NON-CURRENT LIABILITIES
Deferred revenue, long-term	476
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09
Consolidated Statements of Operations and Other Comprehensive Loss
Revenue	(836)
CURRENT LIABILITIES
Deferred revenue	(1,673)
NON-CURRENT LIABILITIES
Deferred revenue, long-term	0
STOCKHOLDERS’ EQUITY
Accumulated (deficit)	1,673		$ (2,500)
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09 | Biopharma Services
Consolidated Statements of Operations and Other Comprehensive Loss
Revenue	(307)
CURRENT LIABILITIES
Deferred revenue	(1,547)		1,900
NON-CURRENT LIABILITIES
Deferred revenue, long-term	0
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09 | Clinical Services
Consolidated Statements of Operations and Other Comprehensive Loss
Revenue	0
CURRENT LIABILITIES
Deferred revenue	0
NON-CURRENT LIABILITIES
Deferred revenue, long-term	0
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09 | Discovery Services
Consolidated Statements of Operations and Other Comprehensive Loss
Revenue	(529)
CURRENT LIABILITIES
Deferred revenue	(126)		$ 600
NON-CURRENT LIABILITIES
Deferred revenue, long-term	0
Calculated under Revenue Guidance in Effect before Topic 606
Consolidated Statements of Operations and Other Comprehensive Loss
Revenue	6,831
CURRENT LIABILITIES
Deferred revenue	78
NON-CURRENT LIABILITIES
Deferred revenue, long-term	992
STOCKHOLDERS’ EQUITY
Accumulated (deficit)	(140,126)
Calculated under Revenue Guidance in Effect before Topic 606 | Biopharma Services
Consolidated Statements of Operations and Other Comprehensive Loss
Revenue	3,351
CURRENT LIABILITIES
Deferred revenue	78
NON-CURRENT LIABILITIES
Deferred revenue, long-term	516
Calculated under Revenue Guidance in Effect before Topic 606 | Clinical Services
Consolidated Statements of Operations and Other Comprehensive Loss
Revenue	2,342
CURRENT LIABILITIES
Deferred revenue	0
NON-CURRENT LIABILITIES
Deferred revenue, long-term	0
Calculated under Revenue Guidance in Effect before Topic 606 | Discovery Services
Consolidated Statements of Operations and Other Comprehensive Loss
Revenue	1,138
CURRENT LIABILITIES
Deferred revenue	0
NON-CURRENT LIABILITIES
Deferred revenue, long-term	$ 476

Organization, Description of 30

Organization, Description of Business, Basis of Presentation, Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements - Acquisition (Details) - USD ($) $ / shares in Units, $ in Thousands	Aug. 15, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]
Goodwill		$ 17,257		$ 17,992
Business Acquisition, Pro Forma Information [Abstract]
Revenue			$ 8,134
Net loss			$ (9,795)
Basic and dilutive net loss per share (in dollars per share)			$ (0.45)
Revenue		7,667	$ 6,966
VivoPharm
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Business combination, consideration, payments to acquire business	$ 1,600
Business combination, consideration transferred, equity issued value	$ 8,100
Business combination, consideration transferred, percentage withheld in escrow	20.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]
Cash	$ 544
Accounts receivable	905
Lab supplies	350
Prepaid expenses and other current assets	60
Fixed assets	765
Intangible assets	3,160
Goodwill	5,960
Accounts payable and accrued expenses	(913)
Deferred revenue	(814)
Deferred rent and other	(222)
Obligations under capital leases	(76)
Total purchase price	$ 9,719
Business Acquisition, Pro Forma Information [Abstract]
Revenue		1,428
Biopharma Services
Business Acquisition, Pro Forma Information [Abstract]
Revenue		3,658	3,719
Discovery Services
Business Acquisition, Pro Forma Information [Abstract]
Revenue		$ 1,667	$ 293

Revenue and Accounts Receivab31

Revenue and Accounts Receivable - Schedule of Revenue by Service Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 7,667	$ 6,966
Biopharma Services
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	3,658	3,719
Clinical Services
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	2,342	2,954
Discovery Services
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 1,667	$ 293

Revenue and Accounts Receivab32

Revenue and Accounts Receivable - Schedule of Accounts Receivable by Service Type (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts	$ (7,003)	$ (6,539)
Accounts receivable, net	10,654	10,958
Biopharma Services
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	3,847	3,746
Clinical Services
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	12,572	12,205
Discovery Services
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	1,238	$ 1,546
India Subsidiary | Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net, held-for-sale	$ 319

Revenue and Accounts Receivab33

Revenue and Accounts Receivable - Schedule of Clinical Services Revenue (Details) - Payor - Revenue	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Product Information [Line Items]
Percentage of revenue	30.00%	43.00%
Medicare
Product Information [Line Items]
Percentage of revenue	9.00%	14.00%
Other insurers
Product Information [Line Items]
Percentage of revenue	16.00%	23.00%
Other healthcare facilities
Product Information [Line Items]
Percentage of revenue	5.00%	6.00%

Revenue and Accounts Receivab34

Revenue and Accounts Receivable - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)company	Mar. 31, 2017USD ($)company
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenue	$ 7,667	$ 6,966
Payor | Testing Volume | Clinical Testing
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of benchmark	17.00%	35.00%
Payor | Sales | 10% or More Clinical Revenue
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of benchmark	10.00%
Number of companies that accounted for approximately 10% or more of revenue | company	0	1
Payor | Sales | Customer One | 10% or More Clinical Revenue
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of benchmark		11.00%
VivoPharm
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenue	$ 1,428
Clinical Services
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenue	$ 2,342	$ 2,954
Revenue, payment terms	6 months

Revenue and Accounts Receivab35

Revenue and Accounts Receivable - Performance Obligations (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-04-01 $ in Millions	3 Months Ended
	Mar. 31, 2018USD ($)
Clinical Services And Discovery Services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Biopharma Services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	2 years
Revenue, remaining performance obligation	$ 27.4

Assets and Liabilities Held f36

Assets and Liabilities Held for Sale (Details) - India Subsidiary - Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations - USD ($)	Mar. 22, 2018	Apr. 26, 2018
Minimum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group, consideration	$ 1,500,000
Disposal group, number of days when transaction is expected to close after plan to sell was approved	30 days
Maximum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group, consideration	$ 2,000,000
Disposal group, number of days when transaction is expected to close after plan to sell was approved	45 days
Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group, consideration		$ 1,900,000
Disposal group, consideration adjustment		$ 300,000

Assets and Liabilities Held f37

Assets and Liabilities Held for Sale - Schedule of Assets and Liabilities Held for Sale (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets held for sale:
Total current assets held for sale	$ 2,058	$ 0
Current liabilities held for sale:
Total current liabilities held for sale	221	$ 0
India Subsidiary | Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations
Current assets held for sale:
Cash and cash equivalents	49
Accounts receivable, net	319
Other current assets	228
Fixed assets, net	628
Goodwill	735
Other	99
Total current assets held for sale	2,058
Current liabilities held for sale:
Accounts payable and accrued expenses	209
Deferred rent and other	12
Total current liabilities held for sale	$ 221

Earnings Per Share - Summary of

Earnings Per Share - Summary of Anti-Dilutive Equivalent Units Outstanding Excluded From Calculation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	13,272	9,196
Common stock purchase warrants (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	10,055	6,608
Stock options (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	2,534	2,520
Restricted shares of common stock (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	683	68

Term Note and Line of Credit -

Term Note and Line of Credit - Additional Information (Details) - USD ($)	Mar. 22, 2017	Mar. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Line of credit		$ 3,510,000	$ 4,137,000
Term note, current portion		$ 6,000,000	$ 6,000,000
Silicon Valley Bank | Line of Credit
Debt Instrument [Line Items]
Debt instrument term	2 years
Line of credit, maximum borrowing capacity (not to exceed)	$ 6,000,000
Line of credit, maximum borrowing capacity, percent of accounts receivable	80.00%
Line of credit, facility, maximum borrowing capacity, percentage of net collectable value of third party accounts receivable	50.00%
Line of credit, facility, maximum borrowing capacity, times the average monthly collection amount of third party receivables over a previous quarter	3
Effective interest rate		6.25%
Line of credit facility, unused capacity, commitment fee	0.25%
Line of credit		$ 3,500,000
Silicon Valley Bank | Line of Credit | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%
PFG | Secured Debt
Debt Instrument [Line Items]
Debt instrument term	3 years
Effective interest rate	11.50%
Term note, principal balance	$ 6,000,000
Debt instrument, interest rate, effective percentage upon achieving certain milestones set forth by lender	11.00%
Warrants, exercise period	7 years
Warrants, number of shares of common stock with right to purchase (in shares)	443,262
Warrants, exercise price (usd per share)	$ 2.82
Term note, current portion		$ 6,000,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details)	May 10, 2018$ / sharesshares	May 31, 2014$ / sharesshares	Mar. 31, 2018USD ($)stock_planshares	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans | stock_plan			2
Options granted maximum exercisable period (up to)			10 years
Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options granted | $			$ 1,463,020
Unrecognized compensation cost related to non-vested stock options granted expect to recognize, period (in years)			2 years 3 months 11 days
Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of shares under stock options issued (in shares)		200,000
Exercise price of options exchanged (usd per share) | $ / shares		$ 15.89
Non-Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield				0.00%
2011 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future awards (in shares)			693,161
2008 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future awards (in shares)			134,546
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield			0.00%	0.00%
Restricted shares of common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options granted expect to recognize, period (in years)			1 year 3 months 15 days
Unrecognized compensation cost | $			$ 155,911
Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)	661,000
Options exercise price (in usd per share) | $ / shares	$ 0.89
Subsequent Event | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)	350,000
Subsequent Event | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	5 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Employee and Nonemployee Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Options Outstanding, Number of Shares Outstanding
Outstanding, beginning balance (in shares)	2,844,000
Canceled or expired (in shares)	(310,000)
Outstanding, ending balance (in shares)	2,534,000	2,844,000
Exercisable March 31, 2018 (in shares)	1,749,000
Options Outstanding, Weighted-Average Exercise Price
Outstanding, beginning balance (usd per share)	$ 7
Cancelled or expired (usd per share)	5.13
Outstanding, ending balance (usd per share)	7.23	$ 7
Exercisable March 31, 2018 (usd per share)	$ 9.02
Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value
Weighted- Average Remaining Contractual Term, Outstanding (in years)	5 years 8 months 12 days	6 years 11 months 16 days
Weighted- Average Remaining Contractual Term, Exercisable (in years)	4 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding	$ 0	$ 4
Aggregate Intrinsic Value, Exercisable	$ 0

Stock-Based Compensation - Weig

Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate Fair Value of Options Granted (Details) - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Non-Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility		77.41%
Risk free interest rate		2.22%
Dividend yield		0.00%
Term (years)		7 years 1 month 21 days
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility		73.57%
Risk free interest rate		2.03%
Dividend yield	0.00%	0.00%
Term (years)		6 years
Weighted-average fair value of options granted during the period (usd per share)		$ 1.63

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Award Activity (Details) - Restricted shares of common stock	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Number of Shares (in shares):
Non-vested, beginning balance (in shares) | shares	91,000
Vested (in shares) | shares	(2,000)
Cancelled (in shares) | shares	(20,000)
Non-vested, ending balance (in shares) | shares	69,000
Weighted-Average Grant Date Fair Value (in dollars per share):
Non-vested, beginning balance (usd per share) | $ / shares	$ 4.21
Vested (usd per share) | $ / shares	6.30
Cancelled (usd per share) | $ / shares	6.50
Non-vested, ending balance (usd per share) | $ / shares	$ 3.48

Stock-Based Compensation - Effe

Stock-Based Compensation - Effects of Stock-Based Compensation Related to Stock Option Awards (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	$ 274	$ 435
Cost of revenues
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	91	59
Research and development
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	15	50
General and administrative
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	158	300
Sales and marketing
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	$ 10	$ 26

Warrants - Summary of Warrant A

Warrants - Summary of Warrant Activity (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share) | $ / shares	$ 3.8
Warrants Outstanding (in shares) | shares	10,055
Warrant Issued With | Non-derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share) | $ / shares	$ 6
Warrants Outstanding (in shares) | shares	3,969
Warrant Issued For | Derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share) | $ / shares	$ 2.36
Warrants Outstanding (in shares) | shares	6,086
Financing | Warrant Issued With | Non-derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share) | $ / shares	$ 10
Warrants Outstanding (in shares) | shares	243
Financing | Warrant Issued With | Non-derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share) | $ / shares	$ 15
Warrants Outstanding (in shares) | shares	276
2017 Debt | Warrant Issued For | Derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share) | $ / shares	$ 2.82
Warrants Outstanding (in shares) | shares	443
2015 Offering | Warrant Issued With | Non-derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share) | $ / shares	$ 5
Warrants Outstanding (in shares) | shares	3,450
2016 Offerings | Warrant Issued For | Derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share) | $ / shares	$ 2.25
Warrants Outstanding (in shares) | shares	1,968
2017 Offering | Warrant Issued For | Derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share) | $ / shares	$ 2.35
Warrants Outstanding (in shares) | shares	3,500
2017 Offering | Warrant Issued For | Derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share) | $ / shares	$ 2.5
Warrants Outstanding (in shares) | shares	175

Fair Value of Warrants - Summar

Fair Value of Warrants - Summary of Derivative Warrant Activity (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Class of Warrants Outstanding [Roll Forward]
Fair value of warrants outstanding as of December 31, 2017	$ 4,403
Change in fair value of warrants	(692)
Fair value of warrants outstanding as of March 31, 2018	3,711
2017 Debt
Class of Warrants Outstanding [Roll Forward]
Fair value of warrants outstanding as of December 31, 2017	501
Change in fair value of warrants	(78)
Fair value of warrants outstanding as of March 31, 2018	423
2016 Offerings
Class of Warrants Outstanding [Roll Forward]
Fair value of warrants outstanding as of December 31, 2017	1,929
Change in fair value of warrants	27
Fair value of warrants outstanding as of March 31, 2018	1,956
2017 Offering
Class of Warrants Outstanding [Roll Forward]
Fair value of warrants outstanding as of December 31, 2017	1,973
Change in fair value of warrants	(641)
Fair value of warrants outstanding as of March 31, 2018	$ 1,332

Fair Value of Warrants - Assump

Fair Value of Warrants - Assumptions Used in Computing Fair Value of Derivative Warrants (Details) - $ / shares	Mar. 31, 2017	Mar. 31, 2018	Dec. 31, 2017
2017 Debt
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)	$ 2.82	$ 2.82	$ 2.82
Expected life (years)	7 years	5 years 11 months 23 days	6 years 2 months 19 days
Expected volatility	74.61%	73.43%	74.18%
Risk-free interest rate	2.22%	2.56%	2.33%
Expected dividend yield	0.00%	0.00%	0.00%
2016 Offerings
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)	$ 2.25	$ 2.25	$ 2.25
Expected life (years)	4 years 9 months 15 days	3 years 9 months 29 days	4 years 29 days
Expected volatility	76.29%	100.00%	73.44%
Risk-free interest rate	1.94%	2.39%	2.11%
Expected dividend yield	0.00%	0.00%	0.00%
2017 Offering
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)		$ 2.36	$ 2.36
Expected life (years)		1 year 2 months 9 days	1 year 5 months 5 days
Expected volatility		76.78%	77.55%
Risk-free interest rate		2.09%	1.83%
Expected dividend yield		0.00%	0.00%

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair value measurements, recurring - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 3,711	$ 4,403
Note payable	139	156
Total liabilities fair value	3,850	4,559
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0	0
Note payable	0	0
Total liabilities fair value	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0	0
Note payable	0	0
Total liabilities fair value	0	0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	3,711	4,403
Note payable	139	156
Total liabilities fair value	$ 3,850	$ 4,559

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (loss) due to change in value of note payable	$ (17)	$ 232
Repayments of notes payable	0	4,667
Gain due to expiration of warrant liability	$ 692	(7,294)
VenturEast | BioServe
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Number of shares associated with notes payable (in shares)	84,278
Gain (loss) due to change in value of note payable	$ 17	(232)
2016 Offerings | Significant Unobservable Inputs (Level 3) | Fair value measurements, recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain due to expiration of warrant liability	$ 692
Loss on derivative warrants due to change in stock-price		$ (7,294)

Fair Value Measurements - Sum50

Fair Value Measurements - Summary of Fair Value of Notes Payable (Details) - Significant Unobservable Inputs (Level 3) - Fair value measurements, recurring $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Notes Payable to VenturEast | VenturEast
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 156
Change in fair value	(17)
Ending balance	139
Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	4,403
Change in fair value	(692)
Ending balance	$ 3,711

Joint Venture Agreement - Addit

Joint Venture Agreement - Additional Information (Details) - USD ($)	3 Months Ended		59 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	May 31, 2013
Schedule of Equity Method Investments [Line Items]
Joint venture net loss	$ 2,000	$ 12,000
Research and development
Schedule of Equity Method Investments [Line Items]
Joint venture net loss	2,000	$ 12,000
Equity Method Investee
Schedule of Equity Method Investments [Line Items]
Due from related parties, current	$ 10,000		$ 10,000
Joint Venture Agreement
Schedule of Equity Method Investments [Line Items]
Percentage of outstanding membership interests in joint venture				50.00%
Investment in joint venture			$ 2,000,000
Fair value of capital contribution in joint venture				$ 6,000,000
Joint Venture Agreement | Maximum
Schedule of Equity Method Investments [Line Items]
Required payments to acquire interest in joint venture				$ 6,000,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 30, 2014	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2016
Equity Dynamics, Inc.
Related Party Transaction [Line Items]
Agreement with related party, fee	$ 10,000
Agreement with related party, consulting fee		$ 30,000	$ 30,000
Due to related party		20,000
Dr. Chaganti
Related Party Transaction [Line Items]
Option to purchase shares under consulting agreement (in shares)				200,000
Common stock, shares purchased price per share (usd per share)				$ 15.89
Award vesting period				4 years
Dr. Chaganti | Consulting and Advisory Agreement
Related Party Transaction [Line Items]
Non-cash stock-based compensation expense		$ 0	$ 25,625

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event - USD ($)	May 10, 2018	May 14, 2018	Apr. 26, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Options granted (in shares)	661,000
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | India Subsidiary
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group, consideration			$ 1,900,000
Disposal group, consideration adjustment			$ 300,000
Chief Executive Officer
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Officer salary	$ 350,000
Options granted (in shares)	350,000
Silicon Valley Bank | Line of Credit
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Debt instrument, covenant, required proceeds from issuance of subordinated debt or from the sale of equity securities		$ 2,500,000